Tuberculosis (TB) is a deadly global health crisis despite being a curable disease. In 2023 alone, TB killed about 1.25 million people globally — more than any other infectious pathogen. While the ability of months- or years-long courses of antibiotics to kill Mycobacterium tuberculosis, the bacteria that cause the disease, treatment success is not certain for all. In fact, in approximately 12% of patients, TB recurs even after treatment.
The major roadblock is that clinicians today lack a specific test to see if TB bacteria were completely removed from the body by treatment. Failing to have accurate monitoring mechanisms, doctors have to implement the same six-month treatment regimen in all patients and accept that some will be over-treated and some will be failures. However, all that may soon change, thanks of a breakthrough RNA-based TB detection test that Dr. Kayvan Zainabadi, assistant professor of molecular microbiology at Weill Cornell Medicine, and his India-based team are developing.
Modern TB treatment protocols are dependent on clinical experience and sputum-based diagnostic procedures that identify bacterial DNA. However, these procedures are fraught with limitations. Despite the successful treatment, residual bacterial DNA can continue to be present in the patient's system, resulting in false positives and making it difficult to clearly perceive the status of the disease.
This diagnostic imprecision compels physicians to remain with a "one-size-fits-all" six-month treatment regimen, even when evidence indicates that most patients might be cured earlier. Long-term exposure to highly effective antibiotics not only risks patients developing side effects but also places a heavy burden on healthcare systems, particularly in low-resource settings where TB is most prevalent.
Dr. Zainabadi’s research introduces a groundbreaking concept: using ribosomal RNA (rRNA) as a rapid, sensitive, and accurate marker of TB infection. Unlike DNA, RNA is inherently less stable and degrades quickly after bacterial death, minimizing the risk of false positives.
The innovation is aimed at the detection of the 16S rRNA of Mycobacterium tuberculosis, which is a part essential to bacterial protein synthesis. Its prevalence in the cell makes it a prime target for detection even in small or difficult-to-access samples.
Significantly, this RNA-based method might overcome the sputum reliance that is sometimes tricky to obtain from high-risk populations such as children or HIV-infected individuals. Rather, less intrusive sample forms might be utilized, providing a more patient-centered, convenient, and scalable platform.
The RNA test operates by extracting 16S rRNA from patient samples and amplifying it using highly sensitive molecular methods. Since rRNA degrades quickly after bacterial cells die, detecting it gives real-time feedback regarding the presence of active TB infection — something DNA-based tests cannot consistently provide.
In practice, a sample would be taken from the patient (possibly from gastric fluid, blood, or other more readily accessible fluids) and run through the RNA detection system. If live bacteria are present, the 16S rRNA signature would show up in the test results, providing clinicians with an instant readout of disease activity.
The rapidity and precision of this methodology may significantly reduce diagnostic turnaround times from weeks or months to mere minutes or hours. This results in quicker clinical decisions, more targeted interventions, and substantial reductions in patient anxiety and healthcare expenditures.
In comparison to conventional sputum microscopy and DNA-based molecular diagnostics, the RNA-based test has a number of revolutionary benefits.
First, its ability to target active infection — not just bacterial residue — prevents patients from being subjected to unnecessary or excessive treatment. This specificity is especially important in combating multidrug-resistant TB, where inappropriately using antibiotics exacerbates resistance problems.
Secondly, the fact that it can accept non-sputum samples makes it much more convenient. It is not possible for several children and immunocompromised individuals to produce sufficient sputum, and clinicians are left with the option of using invasive and less effective gastric lavage methods. An RNA-based test would equalize access to proper TB diagnosis among these high-risk populations.
Third, in the field of TB drug discovery, this test might be a game-changer. Rather than waiting two years to determine if a drug is effective, researchers would be able to monitor bacterial clearance in real-time, moving clinical trials forward more quickly and lowering costs.
Lastly, at a macro health systems level, a quick, precise, and less intrusive diagnostic device would be a game-changer for TB-endemic countries where resources are tightly constrained and the disease burden is highest.
The stakes are as high as they could possibly be. TB has continued to be a recalcitrant worldwide killer, too often fueled by diagnostic ambiguity and treatment inefficacy. An RNA-based diagnostic test such as the one Dr. Zainabadi and his colleagues are creating is not only an incremental step but a potential paradigm shift in how we combat the disease.
As the study continues, the expectation is that this new technology will not only revolutionize individual patient treatment but also redefine the public health sector in the global fight against tuberculosis.
Credits: Canva
A new ketamine-like nasal spray will soon be available at a subsidised cost in Australia to help thousands living with treatment-resistant depression. The medication, called Spravato (esketamine), has been added to the Pharmaceutical Benefits Scheme (PBS), marking a significant shift in how the country approaches difficult-to-treat mental health conditions.
Esketamine is chemically related to ketamine, a well-known anaesthetic that gained notoriety for recreational use in rave culture. However, in controlled medical settings, this compound is offering new hope for patients who have not responded to traditional antidepressants.
Unlike older medications that target serotonin – a “feel-good” chemical in the brain – esketamine works on a different neurotransmitter called glutamate. This chemical is believed to play a key role in restoring neural connections that influence mood regulation. The result is often a much faster response, with some patients feeling relief within hours instead of weeks or months.
Esketamine is the first government-funded drug for major depression in over 30 years that works via a new mechanism. While most antidepressants developed since the 1980s have focused on serotonin or other monoamines, esketamine offers an alternative path by targeting glutamate and related brain circuits.
For those who have tried multiple medications without success, this drug represents a long-awaited option. Clinical trials in Australia show that nearly 50% of patients with treatment-resistant depression reported significant improvement after using esketamine.
Starting Thursday, up to 30,000 Australians will be able to access Spravato through the PBS. Patients will pay $31.60 per dose, or $7.70 for pensioners and concession card holders. However, this does not include additional healthcare and administrative fees. Because of safety requirements, the drug must be administered under supervision at certified treatment centres, which will add to the overall cost.
Despite these extra expenses, making esketamine available through PBS is expected to reduce financial barriers and give more Australians access to potentially life-changing care.
Since receiving approval from the US Food and Drug Administration (FDA) in 2019, esketamine has been used in hospitals and clinics across America, particularly in emergency care for severe depression. Unlike some drugs that sedate or numb emotions, esketamine is reported to alleviate core depressive symptoms — including intense feelings of hopelessness and suicidal thoughts — without dulling awareness.
Mental health experts say this rapid effect can be life-saving in critical cases where waiting for standard medications to take effect is not an option.
The inclusion of Spravato in the PBS comes after a four-year wait and four separate funding submissions. The listing is seen as a major win for mental health advocates and patients who have pushed for broader access to advanced treatments.
While it may not work for everyone, esketamine opens a new chapter in treating depression — one focused on faster, more targeted relief for those who need it most.
Credit: Canva
British King Charles recently reflected on his experience with cancer, saying it brought into "sharp focus the very best of humanity", while acknowledging that each new case is "a daunting and at times frightening experience" for those receiving a diagnosis and for their loved ones. The British monarch was diagnosed with an enlarged prostate gland in February last year, after which he has been getting regular treatments and receiving outpatient care. Despite the diagnosis at 77 years, he has remained positive about his treatment and has continued to perform some of his constitutional duties, such as paperwork and private meetings.
In a personal written message, released to coincide with a Buckingham Palace reception celebrating organisations that help people with the disease, he described himself as one of the "statistics" among the 390,000 who "sadly" receive a cancer diagnosis in the UK each year. He said it "can also be an experience that brings into sharp focus the very best of humanity". Notably, he told the representatives of the cancer charity that they have the British royal family's "deepest admiration."
King Charles hailed the late Dame Deborah James as an inspiration, quoting her final message and encouraging everyone to follow her example. "Find a life worth enjoying; take risks; love deeply; have no regrets; and always, always have rebellious hope." A royal source said there was no update on the king’s condition or treatment, but that it continued in a "very positive direction", reflected in his "very full" national and international diary. They described the words and subject of the message as "deeply personal" for the king.
While Buckingham Palace has not made an announcement clarifying the type of cancer the 76-year-old monarch has been battling but it is suspected that he might have prostate cancer. As described by UK NHS, prostate cancer is a type of cancer that occurs when malignant cells form in the prostate gland, which is a walnut-sized gland in the male reproductive system. Prostate cancer treatment guidelines have shifted their path a bit in recent years, with many men opting for active surveillance rather than immediate treatment for slow-growing tumours. However, about 50% of men on "watchful waiting" will require further treatment within 5 years because of the tumour progression. This is what triggered many researchers to aim and identify whether dietary modifications, specifically increasing omega-3 fatty acids, could prolong this surveillance period and slow down the tumour progression.
Credits: Canva
The UK Health Security Agency (UKHSA) has urged travellers to the Kingdom of Saudi Arabia (KSA) for Umrah and the upcoming pilgrimages to ensure they are vaccinated against meningococcal disease with the MenACWY vaccine. This notice has been issued in the backdrop of the ongoing outbreaks of serogroup W (MenW) disease, which is associated with travel to KSA.
As of now, UKHSA has confirmed 5 cases of MenW disease between February and March 2025 in people who had recently returned from KSA or had close contacts with those who returned to England and Wales.
As per the 2014 study published in Cambridge University Press, these strains have been emerging throughout the current century with most of the isolates belonging to the sequence type (ST11)/electrophoretic type (ET37) clonal complex (ST11/E37 CC). This has been particular since the international outbreak following Hajj 2000.
Meningococci are capsulated bacteria. The international emergency was first reported following the annual Hajj season in Saudi Arabia in March 2000. This is a serious bacterial infection that can lead to severe illness and even death. It is characterized by the onset and can manifest in various ways, including meningitis, septicemia and pneumonia. MenW IMD has increased in the recent years.
It can start with a high fever, headache, stiff neck, vomiting, and a petechial or purpuric rash.
In some cases there could be atypical presentations too, especially when the patient has pneumonia, septic arthritis, and upper respiratory or ophthalmological symptoms.
A "2013 strain" is also associated with gastrointestinal symptoms like diarrhea ad vomiting.
Invasive meningococcal disease is rare, however, it is a serious condition. What happens here is that the lining of the brain and spinal cord gets inflamed and thus it can kill people or leave them with life-changing disabilities.
Travellers performing Hajj or Umrah, as well as seasonal workers, must show proof of a valid MenACWY vaccination certificate, issued between 10 days and 3 to 5 years before arriving—depending on the type of vaccine they received. The World Health Organization (WHO) and the National Travel Health Network and Centre (NaTHNaC) also recommend that all travellers to Saudi Arabia consider getting the quadrivalent MenACWY vaccine, especially in light of the ongoing MenW outbreak.
Dr Shamez Ladhani, who is a Consultant Epidemiologist at UKHSA said, "The MenACWY vaccination is essential for pilgrims travelling to KSA for Umrah and Hajj, particularly given recent cases among UK returnees and their families. Meningococcal disease can be fatal and may leave survivors with serious lifelong conditions including hearing loss, brain damage and limb amputations. Pilgrims should ensure vaccination at least ten days before travel and remain vigilant for symptoms like sudden fever, severe headache, stiff neck, or rash. If you or anyone at home becomes unwell with any symptoms of meningitis within two weeks of returning from Saudi Arabia, contact your GP or NHS 111, mentioning your recent travel history, or dial 999 in case of emergency."
© 2024 Bennett, Coleman & Company Limited